Type I reaction of Hansen's disease with exposure to adalimumab: a case report.
Oberstein
Elana M
EM
Division of Rheumatology and Immunology, Miller School of Medicine, Miami, Florida 33136, USA. eoberstein@med.miami.edu
Kromo
Olga
O
Tozman
Elaine C
EC
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000175:diagnosis*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy; D003951:Diagnostic Errors; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007918:Leprosy / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha